Literature DB >> 10428060

Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices.

P J King1, P S Widdowson, H N Doods, G Williams.   

Abstract

Neuropeptide Y (NPY) is an important regulator of energy balance in mammals through its orexigenic, antithermogenic, and insulin secretagogue actions. We investigated the regulation of endogenous NPY release from rat hypothalamic slices by NPY receptor ligands and calcium channel antagonists. High-potassium stimulation (60 mM) of the slices produced a calcium-dependent threefold increase in NPY release above basal release. The Y2 receptor agonists NPY(13-36) and N-acetyl[Leu28,Leu31]NPY(24-36), the Y4 agonist rat pancreatic polypeptide (rPP), and the Y4/Y5 agonist human pancreatic polypeptide (hPP) significantly reduced both basal and stimulated NPY release. NPY(13-36)-induced reduction of NPY release could be partially prevented in the presence of the weak Y2 antagonist T4-[NPY(33-36)]4, whereas the hPP- and rPP-induced inhibition of release was not affected by the Y5 antagonist CGP71683A or the Y1 antagonist BIBP3226. The selective Y1, Y2, and Y5 antagonists had no effect on either basal or potassium-stimulated release when administered alone. The calcium channel inhibitors omega-conotoxin GVIA (N-type), omega-agatoxin TK (P/Q-type), and omega-conotoxin MVIIC (Q-type) all significantly inhibited potassium-stimulated NPY release, without any effect on basal release, whereas nifedipine had no effect on either basal or stimulated release. Addition of both omega-conotoxin GVIA and omega-agatoxin TK together completely inhibited the potassium-stimulated release. In conclusion, we have demonstrated that NPY release from hypothalamic slices is calcium-dependent, involving N-, P-, and Q-type calcium channels. NPY release is also inhibited by Y2 agonists and rPP/hPP, suggesting that Y2 and Y4 receptors may act as autoreceptors on NPY-containing nerve terminals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428060     DOI: 10.1046/j.1471-4159.1999.0730641.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  29 in total

Review 1.  Neuroendocrine regulation of eating behavior.

Authors:  R Vettor; R Fabris; C Pagano; G Federspil
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

2.  Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype.

Authors:  Cigdem Aydin; Ozge Oztan; Ceylan Isgor
Journal:  Behav Brain Res       Date:  2011-04-08       Impact factor: 3.332

3.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

Review 4.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 5.  Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y.

Authors:  Mallory E Bowers; Dennis C Choi; Kerry J Ressler
Journal:  Physiol Behav       Date:  2012-03-10

6.  Sizing up pharmacotherapy for obesity.

Authors:  Michael A Valentino; Andre Terzic; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

7.  Central neuropeptide Y modulates binge-like ethanol drinking in C57BL/6J mice via Y1 and Y2 receptors.

Authors:  Angela M Sparrow; Emily G Lowery-Gionta; Kristen E Pleil; Chia Li; Gretchen M Sprow; Benjamin R Cox; Jennifer A Rinker; Ana M Jijon; José Peňa; Montserrat Navarro; Thomas L Kash; Todd E Thiele
Journal:  Neuropsychopharmacology       Date:  2012-01-04       Impact factor: 7.853

8.  Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.

Authors:  K L Seldeen; P G Halley; C H Volmar; M A Rodríguez; M Hernandez; M Pang; S K Carlsson; L J Suva; C Wahlestedt; B R Troen; S P Brothers
Journal:  Neuropeptides       Date:  2017-11-07       Impact factor: 3.286

9.  Glucokinase activity in the arcuate nucleus regulates glucose intake.

Authors:  Syed Hussain; Errol Richardson; Yue Ma; Christopher Holton; Ivan De Backer; Niki Buckley; Waljit Dhillo; Gavin Bewick; Shuai Zhang; David Carling; Steve Bloom; James Gardiner
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

10.  Neuropeptide Y release in the rat spinal cord measured with Y1 receptor internalization is increased after nerve injury.

Authors:  Juan Carlos Marvizon; Wenling Chen; Weisi Fu; Bradley K Taylor
Journal:  Neuropharmacology       Date:  2019-08-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.